Randomized trial · people
CagriSema: HbA1c down 2.33% at 40 weeks in REIMAGINE 3
Checked against the paper Randomized trialPublished by PepVault
The takeaway
For people with type 2 diabetes on basal insulin, adding weekly CagriSema at either tested dose lowered HbA1c clearly more than placebo and came with weight loss, with no severe low blood sugar seen in this trial.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 274
- Published
- 2026
- Journal
- Lancet
What they tested
The team tested whether weekly CagriSema (cagrilintide plus semaglutide) works better than placebo at controlling blood sugar in adults with type 2 diabetes already on daily basal insulin, and whether it is safe.
How the study was done
A randomized, double-blind, placebo-controlled phase 3 trial at 46 centers in six countries, in 274 adults with type 2 diabetes and HbA1c (a 3-month average of blood sugar) of 7.0-10.5% who were on stable once-daily basal insulin, with or without metformin. For 40 weeks they got a weekly shot under the skin of cagrilintide 2.4 mg plus semaglutide 2.4 mg, cagrilintide 1.0 mg plus semaglutide 1.0 mg, or a matching placebo (a dummy shot).

Model. Individual results vary.
What they found
At week 40, HbA1c fell by 2.33% in the 2.4 mg arm and 2.10% in the 1.0 mg arm, against 0.66% on placebo. Compared with placebo, the treatment difference was -1.68 percentage points for the 2.4 mg arm and -1.44 percentage points for the 1.0 mg arm (both p<0.0001). Body weight dropped by 10-12% on CagriSema. Side effects were reported by 80% of the 2.4 mg arm, 71% of the 1.0 mg arm and 71% on placebo, mostly mild or moderate stomach and gut problems, and no one had severe hypoglycemia (dangerously low blood sugar).
What it doesn’t show
The trial ran 40 weeks in 274 people, so it cannot show long-term effects, and it only included adults already on stable basal insulin within a set HbA1c range. It was funded by Novo Nordisk.
The paper
Rosenstock et al. Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study. Lancet. 2026.
The compounds
More studies on CagriSema
- CagriSema: 30.3% hit both BMI and waist-to-height targets at 68 weeksRandomized trial · people · 2026
- CagriSema: 18.4% weight loss vs 11.9% on semaglutide in REDEFINE 5Randomized trial · people · 2026
- CagriSema: 13.7% weight loss at 68 weeks in REDEFINE 2Randomized trial · people · 2025
- Every study on CagriSema
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.